

#### PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

Manuscript NO: 80013

Title: Increased CD4/CD8 Lymphocyte ratio predicts favourable neoadjuvant treatment

response in gastric cancer: A prospective pilot study

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 04427657 Position: Editorial Board Academic degree: MD

**Professional title:** Chief Physician, Professor

Reviewer's Country/Territory: China

**Author's Country/Territory:** Canada

Manuscript submission date: 2022-10-03

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-10-04 02:45

Reviewer performed review: 2022-10-05 10:52

**Review time:** 1 Day and 8 Hours

Scientific quality	[ ] Grade A: Excellent [ ] Grade B: Very good [Y] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Language quality	[ ] Grade A: Priority publishing [ Y] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [ ] Accept (General priority) [ Y] Minor revision [ ] Major revision [ ] Rejection
Re-review	[Y]Yes [ ]No



## **Baishideng Publishing**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-399-1568 E-mail: bpgoffice@wjgnet.com

https://www.wjgnet.com

Peer-Review: [Y] Anonymous [ ] Onymous Peer-reviewer statements Conflicts-of-Interest: [ ] Yes [Y] No

### SPECIFIC COMMENTS TO AUTHORS

The study aimed to investigate the utility of CD4, CD8, Galectin-3 and E-cadherin in neoadjuvant FLOT chemotherapy predicting tumour response gastric adenocarcinoma. And the authors conclude that an elevated CD4+/CD8+ Ratio is a promising immunohistochemistry (IHC)-based biomarker to predict favourable treatment response to FLOT neoadjuvant chemotherapy in locally advanced gastric cancer. It was interesting. However, I have some comments. 1. Core tip section should be reorganized. 2. Some relevant contents should be added in the too simple INTRODUCTION. 3. A flow chart should be used in this study. 4. How to define and obtain the normal specimens should be mentioned in the METHODS. 5. The observers and magnifications should be addressed in the histological analysis. 6. Disadvantages of neoadjuvant chemotherapy in this present study should be involved. 7. The DISCUSSION was too redundant. Please deleted some irrelevant contents and added some relevant mechanisms in the section. 8. Some images (25th Percentile) in Figure 1A were not correct. Please added some arrows in the images.



### PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

Manuscript NO: 80013

Title: Increased CD4/CD8 Lymphocyte ratio predicts favourable neoadjuvant treatment

response in gastric cancer: A prospective pilot study

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 00505755 Position: Editorial Board Academic degree: PhD

**Professional title:** Senior Research Fellow

Reviewer's Country/Territory: Japan

**Author's Country/Territory:** Canada

Manuscript submission date: 2022-10-03

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-10-03 23:54

Reviewer performed review: 2022-10-12 04:44

**Review time:** 8 Days and 4 Hours

Scientific quality	[ ] Grade A: Excellent [Y] Grade B: Very good [ ] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Language quality	[ Y] Grade A: Priority publishing [ ] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [ ] Accept (General priority) [ Y] Minor revision [ ] Major revision [ ] Rejection
Re-review	[ ]Yes [Y]No



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568

E-mail: bpgoffice@wjgnet.com

https://www.wjgnet.com

Peer-reviewer	Peer-Review: [Y] Anonymous [ ] Onymous
statements	Conflicts-of-Interest: [ ] Yes [ Y] No

#### SPECIFIC COMMENTS TO AUTHORS

This study demonstrates that CD4/CD8 ratio distinguish the treatment responsivity to neoadjuvant FLOT chemotherapy. The legend for Figure 2C may be revised to describe models more in detail and the meaning of the solid and dotted lines. The texts citing the Figure 1A, B, and C may be revised to be in order.



#### PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

Manuscript NO: 80013

Title: Increased CD4/CD8 Lymphocyte ratio predicts favourable neoadjuvant treatment

response in gastric cancer: A prospective pilot study

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 02842791

**Position:** Peer Reviewer

Academic degree: MD

**Professional title:** Doctor

Reviewer's Country/Territory: China

Author's Country/Territory: Canada

Manuscript submission date: 2022-10-03

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-10-04 14:13

Reviewer performed review: 2022-10-12 14:24

**Review time:** 8 Days

Scientific quality	[ ] Grade A: Excellent [ ] Grade B: Very good [Y] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Language quality	[ ] Grade A: Priority publishing [ Y] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [ Y] Accept (General priority) [ ] Minor revision [ ] Major revision [ ] Rejection



Re-review	[Y]Yes [ ]No
Peer-reviewer	Peer-Review: [Y] Anonymous [ ] Onymous
statements	Conflicts-of-Interest: [ ] Yes [ Y] No

#### SPECIFIC COMMENTS TO AUTHORS

This study evaluate some potential biomarkers provide predictive value in evaluating treatment response following neoadjuvant FLOT chemotherapy. They demonstrate that an elevated ratio between CD4+ and CD8+lymphocytes is a promising biomarker to predict treatment response to neoadjuvant chemotherapy in locally advanced gastric cancer. However, the small sample size may limit the significance of research findings.



### PEER-REVIEW REPORT

Name of journal: World	Journal o	of Gastrointestinal	Oncology
------------------------	-----------	---------------------	----------

Manuscript NO: 80013

Title: Increased CD4/CD8 Lymphocyte ratio predicts favourable neoadjuvant treatment

response in gastric cancer: A prospective pilot study

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 06344948

**Position:** Peer Reviewer

Academic degree: MD

**Professional title:** Doctor

Reviewer's Country/Territory: Serbia

**Author's Country/Territory:** Canada

Manuscript submission date: 2022-10-03

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-10-08 17:16

Reviewer performed review: 2022-10-21 14:58

**Review time:** 12 Days and 21 Hours

Scientific quality	[ ] Grade A: Excellent [Y] Grade B: Very good [ ] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Language quality	[Y] Grade A: Priority publishing [] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [ ] Accept (General priority) [ Y] Minor revision [ ] Major revision [ ] Rejection



Re-review	[Y]Yes []No
Peer-reviewer	Peer-Review: [Y] Anonymous [ ] Onymous
statements	Conflicts-of-Interest: [ ] Yes [Y] No

#### SPECIFIC COMMENTS TO AUTHORS

This is an interesting pilot study in which the authors investigated the utility of CD4, CD8, Galectin-3 and E-cadherin in predicting neoadjuvant FLOT chemotherapy tumour response in gastric adenocarcinoma. They have convincingly demonstrated that the elevated CD4 + /CD8 + ratio is a promising IHC-based biomarker to predict favourable treatment response to FLOT neoadjuvant chemotherapy. This is a widely investigated and researched topic, as the CD4 + /CD8 + ratio is recognized as a nonspecific immune biomarker for a number of pathological states. This study builds well on the existing clinical trials and available literature and presents new insight into mechanisms related to neoadjuvant FLOT chemotherapy action. A comprehensive statistical analysis supports the main conclusions although with somewhat high error expectations. Although the prognostic significance of CD4 + /CD8 + ratio is confirmed in this study, the small sample size limits the adequate interpretation of the acquired data. I believe that this study is worthy of further investigation and that it can be published after the minor changes. I have minor suggestions: 1. In the Background part the sentence: Predictive biomarkers using immunohistochemistry is one method to inform treatment should be reformulated: Predictive biomarkers detected response bv immunohistochemistry method may provide useful data regarding treatment response. 2. The Introduction part (page 4) is a little bit scarce with data and should begin with more general data, instead with the method that authors have been used in this research. Clinical and epidemiological data demonstrate that gastric cancer (GC) is a highly heterogeneous cancer with a poor prognosis. Patients with the same TNM staging can



# Baishideng

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

exhibit quite different clinical outcomes. Regardless of the innovations of modern screening methods, emerging new drugs, and multidisciplinary management, the prognosis of GC patients still remains poor. I believe these were the main motives for authors to search for new information to guide treatment strategies in clinical practice and to convey this research, and the implementation of these data are needed at the beginning of the text. The purposes of neoadjuvant chemotherapy in gastric cancer also deserve to be discussed in a couple of sentences (the authors may rely on the reference G. Knight, C. C. Earle, R. Cosby et al., "Neoadjuvant or adjuvant therapy for resectable gastric cancer: a systematic review and practice guideline for North America," Gastric Cancer, vol. 16, no. 1, pp. 28–40, 2013). So, these data should be incorporated on the very begging of the Introduction section, followed by the paragraph regarding the FLOT treatment and afterword paragraph regarding the IHC method the authors have applied in this study. Also, more data are needed regarding the role of the tumor microenvironment where the host immune response occurs with the special emphasis on the role of main immunocompetent cells (CD4 and CD8), and clinical significance and 3. In the Introduction section (page 4) the sentence: In interpretation of their ratio. breast cancer, E-cadherin expression has been associated with chemotherapy response, the authors should provide the additional explanation regarding the expression pattern of E-cadherin related to chemotherapy response, so that readers can get insight into the role of this adhesion molecule (in the text adhesion molecular should be changed to adhesion molecule). 4. In the Key words: CD4; CD8; Galectin-3; Neoadjuvant; Response; Gastric Cancer, the term Chemotherapy should be added beside Neoadjuvant, and the term Treatment before Response. 5. In the Introduction part (page 4) the sentence Neoadjuvant chemotherapy is known to cause adverse events, including hospitalization in approximately 25% of patients requires a reference. 6. In Statistical analysis (page 8) in the second paragraph in the sentence The NIR is defined as defined as the largest one



https://www.wjgnet.com

term defined should be erased. 7. In the Discussion section (page 12) in the sentence Irrespective of efficacy, cytotoxic chemotherapy is also associated with....the phrase cytotoxic chemotherapy should be reformulated to cytotoxicity of chemotherapy is also associated....